Targeting Epstein-Barr virus infection as an intervention against multiple sclerosis

Acta Neurologica Scandinavica

Volumn 131, Issue 2, 2015, Pages 69-79

  Jons, D ^a   Sundstrom P ^b   Andersen, O ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Bio banks; Epstein Barr virus; Multiple sclerosis; Neuroepidemiology; Risk factors; Vaccination

Indexed keywords

ACICLOVIR; ATACICEPT; EPSTEIN BARR VIRUS VACCINE; RITUXIMAB; VALACICLOVIR;

ANTIVIRAL THERAPY; ARTICLE; CELL IMMORTALIZATION; COPY NUMBER VARIATION; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS INFECTION; FOLLOW UP; GENETIC RISK; HUMAN; IMMUNIZATION; MONONUCLEOSIS; MULTIPLE SCLEROSIS; PATHOGENESIS; RISK FACTOR; SEROLOGY; VIRUS INFECTION; VIRUS REPLICATION; COMPLICATION; FEMALE; IMMUNOLOGY; PATHOLOGY; VIROLOGY;

EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; MULTIPLE SCLEROSIS; RISK FACTORS;

EID: 84922651710     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12294     Document Type: Article

References (120)

1. Lucas RM, Hughes AM, Lay ML et al. Epstein-Barr virus and multiple sclerosis. J Neurol Neurosurg Psychiatry 2011;82:1142-8.
2. Pender MP. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 2011;17:351-67.
3. Ascherio A, Munger KL. Epstein-barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 2010;5:271-7.
4. Ramagopalan SV, Hoang U, Seagroatt V et al. Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: a descriptive study. J Neurol Neurosurg Psychiatry 2011;82:682-7.
5. Warner HB, Carp RI. Multiple sclerosis and Epstein-Barr virus. Lancet 1981;2:1290.
6. Visscher BR, Detels R, Coulson AH, Malmgren RM, Dudley JP. Latitude, migration, and the prevalence of multiple sclerosis. Am J Epidemiol 1977;106:470-5.
7. Ascherio A, Munger KL, Lennette ET et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001;286:3083-8.
8. Levin LI, Munger KL, O'reilly EJ, Falk KI, Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010;67:824-30.
9. Sundstrom P, Juto P, Wadell G et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004;62:2277-82.
10. Haahr S, Hollsberg P. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol 2006;16:297-310.
11. Haahr S, Koch-Henriksen N, Moller-Larsen A, Eriksen LS, Andersen HM. Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Mult Scler 1995;1:73-7.
12. Sundqvist E, Sundstrom P, Linden M et al. Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun 2012;13:14-20.
13. Pender MP. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun Rev 2009;8:563-8.
14. Pakpoor J, Giovannoni G, Ramagopalan SV. Epstein-Barr virus and multiple sclerosis: association or causation? Expert Rev Neurother 2013;13:287-97.
15. Pakpoor J, Ramagopalan SV. Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: yes. Mult Scler 2013;19:1690-1.
16. Salzer J, Myhr KM. Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: no. Mult Scler 2013;19:1692-3.
17. Levin LI, Munger KL, Rubertone MV et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005;293:2496-500.
18. Delorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006;63:839-44.
19. Lunemann JD, Tintore M, Messmer B et al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 2010;67:159-69.
20. Pakpoor J, Disanto G, Gerber JE et al. The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler 2013;19:162-6.
21. Pohl D, Krone B, Rostasy K et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006;67:2063-5.
22. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007;68:S7-12.
23. Grose C. The many faces of infectious mononucleosis: the spectrum of Epstein-Barr virus infection in children. Pediatr Rev 1985;7:35-44.
24. Melbye M, Ebbesen P, Bennike T. Infectious mononucleosis in Greenland: a disease of the non-indigenous population. Scand J Infect Dis 1984;16:9-15.
25. Takeuchi K, Tanaka-Taya K, Kazuyama Y et al. Prevalence of Epstein-Barr virus in Japan: trends and future prediction. Pathol Int 2006;56:112-6.
26. De-The G, Day NE, Geser A et al. Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study - a review. IARC Sci Publ 1975:3-16.
27. Chan KH, Tam JS, Peiris JS, Seto WH, Ng MH. Epstein-Barr virus (EBV) infection in infancy. J Clin Virol 2001;21:57-62.
28. Alebouyeh M, Peller P, Goetz O, Ameri MA. Comparative study of the prevalence of Epstein-Barr virus infections in Iran and Germany. Monatsschr Kinderheilkd 1984;132:850-1.
29. Leogrande G, Jirillo E. Studies on the epidemiology of child infections in the Bari area (south Italy). VII. Epidemiology of Epstein-Barr virus infections. Eur J Epidemiol 1993;9:368-72.
30. Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med 2010;362:1993-2000.
31. Macsween KF, Crawford DH. Epstein-Barr virus-recent advances. Lancet Infect Dis 2003;3:131-40.
32. Nagy N, Adori M, Rasul A et al. Soluble factors produced by activated CD4+ T cells modulate EBV latency. Proc Natl Acad Sci USA 2012;109:1512-7.
33. Lunemann JD, Edwards N, Muraro PA et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006;129:1493-506.
34. Crawford DH, Macsween KF, Higgins CD et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 2006;43:276-82.
35. Niederman JC, Evans AS, Subrahmanyan L, McCollum RW. Prevalence, incidence and persistence of EB virus antibody in young adults. N Engl J Med 1970;282:361-5.
36. University health physicians and P.H.L.S. Laboratories. Infectious mononucleosis and its relationship to EB virus antibody. A joint investigation by. Br Med J 1971;4:643-6.
37. Santpere G, Darre F, Blanco S et al. Genome-wide analysis of wild-type Epstein-Barr virus genomes derived from healthy individuals of the 1, 000 Genomes Project. Genome Biol Evol 2014;6:846-60.
38. Auwaerter PG. Infectious mononucleosis in middle age. JAMA 1999;281:454-9.
39. Ramagopalan SV, Giovannoni G, Yeates DG, Seagroatt V, Goldacre MJ. Sex ratio of infectious mononucleosis and possible relevance to multiple sclerosis. Mult Scler 2013;19:359-61.
40. Operskalski EA, Visscher BR, Malmgren RM, Detels R. A case-control study of multiple sclerosis. Neurology 1989;39:825-9.
41. Lindberg C, Andersen O, Vahlne A, Dalton M, Runmarker B. Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiology 1991;10:62-5.
42. Nielsen TR, Rostgaard K, Nielsen NM et al. Multiple sclerosis after infectious mononucleosis. Arch Neurol 2007;64:72-5.
43. Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Multiple sclerosis after infectious mononucleosis: record linkage study. J Epidemiol Community Health 2004;58:1032-5.
44. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006;59:499-503.
45. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS ONE 2010;5:1-5.
46. Ramagopalan SV, Valdar W, Dyment DA et al. Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology 2009;32:257-62.
47. Zaadstra BM, Chorus AM, van Buuren S, Kalsbeek H, van Noort JM. Selective association of multiple sclerosis with infectious mononucleosis. Mult Scler 2008;14:307-13.
48. Fleisher G, Henle W, Henle G, Lennette ET, Biggar RJ. Primary infection with Epstein-Barr virus in infants in the United States: clinical and serologic observations. J Infect Dis 1979;139:553-8.
49. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004;350:1328-37.
50. Torring C, Andreasen C, Gehr N, Bjerg L, Petersen T, Hollsberg P. Higher incidence of Epstein-Barr virus-induced lymphocyte transformation in multiple sclerosis. Acta Neurol Scand 2014;130:90-6.
51. Grotto I, Mimouni D, Huerta M et al. Clinical and laboratory presentation of EBV positive infectious mononucleosis in young adults. Epidemiol Infect 2003;131:683-9.
52. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-20.
53. Bachmann S, Kesselring J. Multiple sclerosis and infectious childhood diseases. Neuroepidemiology 1998;17:154-60.
54. Bager P, Nielsen NM, Bihrmann K et al. Childhood infections and risk of multiple sclerosis. Brain 2004;127:2491-7.
55. Dyment DA, Yee IM, Ebers GC, Sadovnick AD. Multiple sclerosis in stepsiblings: recurrence risk and ascertainment. J Neurol Neurosurg Psychiatry 2006;77:258-9.
56. Westerlind H, Ramanujam R, Uvehag D et al. Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. Brain 2014;137:770-8.
57. Mechelli R, Anderson J, Vittori D et al. Epstein-Barr virus nuclear antigen-1 B-cell epitopes in multiple sclerosis twins. Mult Scler 2011;17:1290-4.
58. Nielsen TR, Rostgaard K, Askling J et al. Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Mult Scler 2009;15:431-6.
59. Granberg T, Martola J, Kristoffersen-Wiberg M, Aspelin P, Fredrikson S. Radiologically isolated syndrome-incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review. Mult Scler 2013;19:271-80.
60. Lycke J, Tollesson PO, Frisen L. Asymptomatic visual loss in multiple sclerosis. J Neurol 2001;248:1079-86.
61. Andersen O. Natural history of multiple sclerosis. In: Raine C et al., eds. Multiple sclerosis: a comprehensive text. Edinburgh: Saunders Elsevier, 2008;100-20.
62. Hanlon P, Avenell A, Aucott L, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther 2014;16:R3.
63. Draborg AH, Duus K, Houen G. Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol 2013;2013:535738.
64. Hjalgrim H, Askling J, Rostgaard K et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003;349:1324-32.
65. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 2010;6:156-66.
66. Dobson R, Topping J, Ramagopalan S, Giovannoni G. Towards an endophenotype in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013;84:e2.
67. Dagdelen S, Hascelik G, Bayraktar M. Simultaneous triple organ specific autoantibody profiling in adult patients with type 1 diabetes mellitus and their first-degree relatives. Int J Clin Pract 2009;63:449-56.
68. Haghighi S, Lekman A, Nilsson S, Blomqvist M, Andersen O. Increased CSF sulfatide levels and serum glycosphingolipid antibody levels in healthy siblings of multiple sclerosis patients. J Neurol Sci 2013;326:35-9.
69. Haghighi S, Andersen O, Rosengren L, Bergstrom T, Wahlstrom J, Nilsson S. Incidence of CSF abnormalities in siblings of multiple sclerosis patients and unrelated controls. J Neurol 2000;247:616-22.
70. Krizova L, Kollar B, Jezova D, Turcani P. Genetic aspects of vitamin D receptor and metabolism in relation to the risk of multiple sclerosis. Gen Physiol Biophys 2013;32:459-66.
71. Hawkes C, Boniface D. Risk associated behaviour in premorbid multiple sclerosis: A case-control study. Mult Scler Relat Disord 2014;3:40-7.
72. Thomas R, Macsween KF, McAulay K et al. Evidence of shared Epstein-Barr viral isolates between sexual partners, and low level EBV in genital secretions. J Med Virol 2006;78:1204-9.
73. Crawford DH, Swerdlow AJ, Higgins C et al. Sexual history and Epstein-Barr virus infection. J Infect Dis 2002;186:731-6.
74. Okuno K, Takashima K, Kanai K et al. Epstein-Barr virus can infect rabbits by the intranasal or peroral route: an animal model for natural primary EBV infection in humans. J Med Virol 2010;82:977-86.
75. Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 1995;85:744-50.
76. Balfour HH Jr, Odumade OA, Schmeling DO et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis 2013;207:80-8.
77. Bray PF, Luka J, Culp KW, Schlight JP. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 1992;42:1798-804.
78. Sargsyan SA, Shearer AJ, Ritchie AM et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010;74:1127-35.
79. Tsurumi T, Fujita M, Kudoh A. Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol 2005;15:3-15.
80. Hammerschmidt W, Sugden B. Replication of Epstein-Barr viral DNA. Cold Spring Harb Perspect Biol 2013;5:a013029.
81. Wagner HJ, Munger KL, Ascherio A. Plasma viral load of Epstein-Barr virus and risk of multiple sclerosis. Eur J Neurol 2004;11:833-4.
82. Fraser KB, Haire M, Millar JH, McCrea S. Increased tendency to spontaneous in-vitro lymphocyte transformation in clinically active multiple sclerosis. Lancet 1979;2:715-7.
83. Brinkman CJ, Nillesen WM, Hommes OR. Lymphocyte subpopulations in multiple sclerosis: spontaneous and mitogen-induced activity. Clin Immunol Immunopathol 1984;31:364-70.
84. Munch M, Moller-Larsen A, Christensen T, Morling N, Hansen HJ, Haahr S. B-lymphoblastoid cell lines from multiple sclerosis patients and a healthy control producing a putative new human retrovirus and Epstein-Barr virus. Mult Scler 1995;1:78-81.
85. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164-74.
86. Willis SN, Stadelmann C, Rodig SJ et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009;132:3318-28.
87. Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323-31.
88. Wandinger K, Jabs W, Siekhaus A et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000;55:178-84.
89. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994;36(Suppl):S25-8.
90. Buljevac D, van Doornum GJ, Flach HZ et al. Epstein-Barr virus and disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:1377-81.
91. Torkildsen O, Nyland H, Myrmel H, Myhr KM. Epstein-Barr virus reactivation and multiple sclerosis. Eur J Neurol 2008;15:106-8.
92. Lindsey JW, Hatfield LM, Vu T. Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis. Eur J Neurol 2010;17:1263-9.
93. Jaquiery E, Jilek S, Schluep M et al. Intrathecal immune responses to EBV in early MS. Eur J Immunol 2010;40:878-87.
94. Lycke J, Svennerholm B, Hjelmquist E et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol 1996;243:214-24.
95. Bech E, Lycke J, Gadeberg P et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 2002;58:31-6.
96. Friedman JE, Zabriskie JB, Plank C et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler 2005;11:286-95.
97. Lycke J, Malmestrom C, Stahle L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother 2003;47:2438-41.
98. Lycke J, Andersen O, Svennerholm B, Appelgren L, Dahlof C. Acyclovir concentrations in serum and cerebrospinal fluid at steady state. J Antimicrob Chemother 1989;24:947-54.
99. Tynell E, Aurelius E, Brandell A et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. J Infect Dis 1996;174:324-31.
100. He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2013;12:CD009130.
101. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS ONE 2013;8:e66308.
102. Kappos L, Hartung HP, Freedman MS et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol 2014;13:353-63.
103. Bordi I, Umeton R, Ricigliano VA et al. A mechanistic, stochastic model helps understand multiple sclerosis course and pathogenesis. Int J Genomics 2013;2013:910321.
104. de Jager PL, Chibnik LB, Cui J et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009;8:1111-9.
105. Koch L. Epigenetics: An epigenetic twist on the missing heritability of complex traits. Nat Rev Genet 2014;15:218.
106. Banka S, Ryan K, Thomson W, Newman WG. Pernicious anemia - genetic insights. Autoimmun Rev 2011;10:455-9.
107. Balfour HH Jr. Epstein-Barr virus vaccine for the prevention of infectious mononucleosis-and what else? J Infect Dis 2007;196:1724-6.
108. Macsween KF, Higgins CD, McAulay KA et al. Infectious mononucleosis in university students in the United kingdom: evaluation of the clinical features and consequences of the disease. Clin Infect Dis 2010;50:699-706.
109. Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics 2009;124:189-93.
110. Andersson J. An overview of Epstein-Barr Virus: from discovery to future directions for treatment and prevention. Herpes 2000;7:76-82.
111. Silveira EL, Fogg MH, Leskowitz RM et al. Therapeutic vaccination against the rhesus lymphocryptovirus EBNA-1 homologue, rhEBNA-1, elicits T cell responses to novel epitopes in rhesus macaques. J Virol 2013;87:13904-10.
112. Ruiss R, Jochum S, Wanner G, Reisbach G, Hammerschmidt W, Zeidler R. A virus-like particle-based Epstein-Barr virus vaccine. J Virol 2011;85:13105-13.
113. Rees L, Tizard EJ, Morgan AJ et al. A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 2009;88:1025-9.
114. Sokal EM, Hoppenbrouwers K, Vandermeulen C et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007;196:1749-53.
115. Cui X, Cao Z, Sen G et al. A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine. Vaccine 2013;31:3039-45.
116. Gadoth N. Subacute sclerosing panencephalitis (SSPE) the story of a vanishing disease. Brain Dev 2012;34:705-11.
117. Trepo C. A brief history of hepatitis milestones. Liver Int 2014;34(Suppl 1):29-37.
118. Barroso LF 2nd. The role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infection. Ther Adv Vaccines 2013;1:81-92.
119. Munger KL, Levin LI, O'reilly EJ, Falk KI, Ascherio A. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 2011;17:1185-93.
120. Salzer J, Nystrom M, Hallmans G, Stenlund H, Wadell G, Sundstrom P. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples. Mult Scler 2013.